Prime Medicine Unveils Strategically Focused Pipeline
WEB4 days ago · Building on its efforts in p47 phox CGD, Prime Medicine is advancing a program for X-linked CGD, which utilizes its Prime Assisted Site-Specific Integrate Gene Editing (PASSIGE™) technology, and is expected to address over 90 percent of known mutations in the CYBB gene with a single approach.
Prime Medicine Unveils Strategically Focused Pipeline - Yahoo …
WEB4 days ago · Prime Medicine, Inc. -- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates...
Prime Medicine Announces Strategic Research Collaboration and …
WEB4 days ago · CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME) today announced a strategic research collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
WEB4 days ago · On a company update and news of collaboration with a top healthcare business, investors piled into the gene-editing specialist and sent its share price almost 12% higher today.
Prime Medicine Announces Strategic Research Collaboration and …
WEB4 days ago · CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME) today announced a strategic research collaboration and license agreement with Bristol Myers Squibb...
Press Releases - Prime Medicine, Inc.
WEBMar 1, 2024 · Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine Announces FDA Clearance of Investigational New …
WEBCAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative...
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb …
WEB4 days ago · On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next ...
Gene Editor Prime Medicines Signs BMS Cell Therapy Deal
WEB4 days ago · Gene editing biotech Prime Medicine took two steps forward and one step back Monday, announcing a sizeable partnership with Bristol Myers Squibb worth billions in potential milestones, but also implementing a pipeline re-organization to eke out enough cash to operate into 2026.
Prime Medicine stock rallies 15% on Bristol Myers deal, drug …
WEB4 days ago · Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which includes a $55M equity investment. Read more here.
- Some results have been removed